Canadian Hospital Specialties has been acquired by Cortec Group
Canadian Hospital Specialties Ltd. (CHS), a portfolio company of Hammond, Kennedy, Whitney & Co., Inc. (HKW), has been sold to Cortec Group, a private equity firm, which has recapitalized CHS along with senior management led by the Enns family. Financial terms of this transaction had not been disclosed.
CHS is a leading manufacturer, marketer and distributor of disposable medical and surgical devices primarily to the Canadian hospital market. Founded in 1967, CHS manufactures and sells its own MED-RX® branded products and markets devices under exclusive relationships with third party OEMs.
Cortec Group was founded in 1984 and is based in New York. The company invests in middle market healthcare, consumer, and specialty products, service and distribution businesses.
HKW is a private equity firm founded in 1903 with offices in Indianapolis and New York. Since 1982, HKW has sponsored 44 platform management buyouts of lower middle-market companies throughout North America as well as 47 add-on acquisitions.
One of Oaklins' teams in the USA served as the exclusive financial advisor to the seller in this transaction.
Talk to the deal team
Michael S. Goldman
Oaklins TM Capital
Paul R. Smolevitz
Oaklins TM Capital
Related deals
Briconord has completed its fourth LBO with ODDO BHF
Briconord, a French designer and distributor of furniture and hardware solutions, has been acquired by a consortium of investors led by ODDO BHF in its fourth leveraged buyout (LBO).
Learn moreBolster Investment Partners has acquired a majority stake in Eternal Sun
Bolster Investment Partners, a Netherlands-based investment firm, has acquired a majority stake in Eternal Sun, a global technology leader in advanced solar panel testing equipment, from ABN AMRO Sustainable Impact Fund, a private impact fund based in the Netherlands, and Vermec, a Belgium-based investment firm.
Learn moreCerbios-Pharma has been acquired by HAS Healthcare
Cerbios-Pharma S.A. has been acquired by HAS Healthcare Advanced Synthesis S.A., forming a leading global contract development and manufacturing organization (CDMO) group. This transaction results in a seamless integration of complementary capabilities, combining extensive expertise in production, chemical and biological sciences and technical excellence, all designed to meet the evolving demands of the global pharmaceutical sector.
Learn more